RheumNow Week in Review – 7 October 2016 Save
Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.
- Injection of nanoparticle peptides carrying siRNA that inhibit NF-κB may benefit osteoarthritic joints https://t.co/6KlbF1Dlkr
- FDA grants breakthrough status to Actemra for Rx of giant cell arteritis. Breakthrough=expediated processing by FDA. https://t.co/y6rDS9gr0I
- IRAK3 rs11541076 polymorphism yields 33% increase odds of response to TNFi. NLRP3 rs461266 has 25% fewer responses. https://t.co/qIuf7dJKU3
- Do we need Gout Disease Activity Score (GAS)? Omeract has one based on #Flares last 12mos, SUA, 10cmVAS, TJC, SJC(0-66) https://t.co/27AWesZDvP
- TaSER study 111 RA patients, shows US driven T2T treatment strategy was no more effective than DAS28 driven T2T outcomes https://t.co/3Vjq4pWODp
- Systematic review of gout shows that allopurinol Rx significantly lowers systolic & diastolic BP & creatinine levels https://t.co/F1LbrU1UUA
- Metanalysis shows CCP superior to RF: sensitivity (67 v 69%), specificity (96 v 86%), PLR (12.6 v 4.9), & erosions https://t.co/D9GedlXRZe
- Ortho literature says surgical excision of RA nodules is effective. In my experience the complication rate is high!… https://t.co/TwjN1GUeMx
- CDC Says the Prevalence of Severe Joint Pain is Rising
- The Arthritis Spectrum after Lyme Infection - Something New
- Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis
- BUILD Study - Baricitinib Shows Rapid Efficacy (ACR20: 62 vs 39%) and X-ray Protection
ADD THE FIRST COMMENT
Disclosures
Disclosures
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.